Key takeaways
- Science Corporation implanted PRIMA, a retinal prosthesis, in the first Stargardt disease patient at Sydney Eye Hospital in May, expanding the technology beyond its existing use for geographic atrophy in patients with an incurable inherited eye condition.
- The implant currently provides black-and-white, high-contrast vision with a limited field of view, enabling the first patient to read words during early rehabilitation sessions, with a next-generation device planned for human trials within one year.
- Science Corporation is positioning retinal and brain-computer interface technology as part of a unified strategy to treat multiple neurological and sensory conditions, with longer-term ambitions to understand how the brain creates the mind.
Science Corporation has implanted its PRIMA retinal prosthesis in the first patient with Stargardt disease, an inherited eye condition currently classified as incurable. CEO Max Hodak announced the milestone on stage at TechCrunch Disrupt 2026, describing how the company’s vision-restoring work extends beyond its original medical focus into a broader strategy for brain-computer interface technology.
A New Application for PRIMA
The first Stargardt patient received the PRIMA implant in May at Sydney Eye Hospital in Australia as part of an ongoing clinical trial. During the patient’s first rehabilitation session after implantation, he saw a letter; in the second session, he was able to read a word. Stargardt disease affects roughly 150,000 people worldwide who have experienced vision loss, gradually destroying the light-sensing cells of the outer retina while potentially leaving the inner retina intact.
PRIMA has already been commercialized in Europe for patients with geographic atrophy, an advanced form of age-related macular degeneration. Applying the technology to Stargardt disease represents a significant expansion of the device’s scope, targeting a disease without existing cures. Hodak positioned the shift as part of Science Corporation’s larger mission to demonstrate that its neural engineering approach can address multiple conditions affecting vision and cognition.
How the Implant Restores Vision
The Surgical Procedure and Device Design
The procedure takes approximately one hour and places a 2mm by 2mm chip at the back of the eye, in the region where photoreceptors have deteriorated. Patients then wear camera-equipped glasses that capture a view of the world and transmit it wirelessly to the implant, which functions as artificial photoreceptors. The device sends electrical signals down the optic nerve to the brain, bypassing the damaged photoreceptors entirely.
Current Capabilities and Limitations
The vision provided by PRIMA is black and white, high-contrast, and sharp, though Hodak acknowledged the field of view remains severely restricted. Patients can see a couple of letters at a time, as if looking through a narrow straw. This limitation stems partly from the device’s small size and the curvature of the eye, which constrains how many electrodes can be densely packed.
The Path to Better Acuity
Science Corporation has mapped a clear trajectory for improvement. A next-generation implant is in development and expected to reach human trials within one year. Over the next five years, the company aims to achieve visual acuity approaching native levels by increasing the field of view and shrinking electrodes to gain finer detail resolution. Hodak noted that smaller electrodes would allow the brain to process information at a resolution closer to what biological photoreceptors provide naturally.
From Vision to Brain-Computer Interfaces
A Unified View of Neural Engineering
Hodak framed PRIMA and Science Corporation’s broader work within a single conceptual umbrella. He described cochlear implants, retinal prostheses, and motor prostheses as different types of brain-computer interfaces, unified by the principle that the brain interprets the world through electrical signals. To the brain, he explained, vision is electrical activity transmitted down the optic nerve; the same logic applies to other neural functions.
Diverging from Neuralink’s Approach
Science Corporation’s brain-computer interface sensor differs significantly from Neuralink’s design. While Neuralink implants electrodes directly into brain tissue, Science Corporation’s device rests on top of the brain inside the skull. Hodak highlighted the advantage of this approach for certain applications, particularly the ability to form connections across distant brain regions and potentially introduce new functional areas—capabilities he suggested would be impossible with conventional electrodes.
Multiple Clinical Applications
Beyond vision restoration, Science Corporation is pursuing its first clinical indication in a neurodegenerative disease that has not been publicly named. The company is also investigating stroke recovery, where a patient who has lost brain tissue due to stroke could theoretically regain lost functions by forming new connections between healthy brain regions. The long-term mission extends further: Hodak described the company’s goal as understanding how the brain creates the mind and learning to build engineered brains.
Why Science Corporation Started With Vision
Hodak founded Science Corporation in 2021 after stepping down as president and co-founder of Neuralink. Rather than immediately pursuing ambitious brain-computer interface applications, the company chose to prove its methods and establish a sustainable business model by working with vision restoration first. This approach allowed the company to validate its core neural engineering technology in a medical context with clear, measurable outcomes before expanding into more complex neurological applications.
The Stargardt trial demonstrates this strategy in action. By successfully treating an incurable disease with an implantable device, Science Corporation accumulates clinical evidence, regulatory approval pathways, and real-world data that can inform development of its broader BCI platform.
Timeline and the Ubiquity of Brain Interfaces
Hodak articulated an ambitious vision for brain-computer interface adoption. While Science Corporation is not designing devices for healthy 40-year-olds, he suggested that many people will eventually use some form of BCI. The company’s internal thinking suggests that individuals may require such technology by their 60s or 70s to maintain health span—not merely lifespan—as cognitive and sensory decline becomes more prevalent.
This perspective reframes BCIs from niche medical devices to potential healthcare infrastructure, similar to how hearing aids and eyeglasses became widespread. If that vision materializes, the next several years will determine whether Science Corporation can accelerate the path from treating individual diseases to managing broad categories of neurological decline.
What the Stargardt Milestone Signals
The first successful implant in a Stargardt patient validates Science Corporation’s hardware, surgical techniques, and rehabilitation protocols. It also signals that the company has cleared regulatory hurdles for a new disease indication. Each successful patient outcome strengthens the foundation for future applications—whether more advanced retinal prostheses, brain interfaces for stroke recovery, or interventions for neurodegenerative diseases that have so far resisted effective treatment.
Source: TechCrunch
Frequently Asked Questions
What is Stargardt disease and why is it significant that PRIMA is being tested for it?
Stargardt disease is an inherited eye condition that gradually destroys light-sensing cells in the outer retina, causing a central blind spot that worsens over time. Approximately 150,000 people worldwide have lost vision to the disease, which is currently considered incurable. PRIMA has been commercialized in Europe for geographic atrophy, but applying it to Stargardt represents the first expansion of the technology to a different incurable eye disease.
How does the PRIMA implant provide vision to patients?
A 2mm by 2mm chip is surgically placed at the back of the eye where photoreceptors have degenerated. Patients wear camera-equipped glasses that capture the visual scene and transmit it wirelessly to the implant, which functions as artificial photoreceptors by converting the image into electrical signals that travel down the optic nerve to the brain. The current implant provides black-and-white, high-contrast vision through a very narrow field of view.
What are Science Corporation's longer-term ambitions beyond vision restoration?
Science Corporation is developing a brain-computer interface sensor implanted inside the skull that rests on top of the brain, distinct from Neuralink's approach of implanting directly into brain tissue. The company is pursuing applications in neurodegenerative diseases and stroke recovery, with a stated long-term mission to understand how the brain creates the mind and eventually build engineered brains capable of replacing or restoring lost neural function.
